Introduction {#Sec1}
============

Conventional chemotherapy, radiotherapy, and surgery were previously the mainstay treatment options available to cancer patients. However, rapid advancements in medical science have led to the development of novel molecular targeted therapies that specifically focus on the biological pathways of cancer cells while sparing the healthy cells. However, due to complex and tightly intertwined cellular regulation processes between cancer cell proliferation and cardiovascular biology, many have resulted in cardiotoxicity.

Cancer drug-induced cardiotoxicity (CDIC) and cancer radiation-induced cardiotoxicity (CRIC) are burgeoning clinical problems. Heart failure is the most common form of CDIC, but this field also comprises hypertension, arrhythmias, ischemia, thromboembolism, valvular heart disease, and sudden cardiac death. Some of these cardiac complications such as arrhythmias and ischemia can occur acutely during cancer treatment, but others such as heart failure and CRIC usually present years after completion of treatment. These cardiac sequelae are more apparent now because early malignancy detection and more efficacious cancer therapies have substantially improved cancer survivorship.

In the United Kingdom, the percentage of breast cancer patients who live at least 10 years beyond their diagnosis date has risen from 40% in the early 1970s to 78% in 2010 \[[@CR1]\], and the 5-year survival rate for childhood cancers diagnosed from 2006 to 2010 has reached 82% \[[@CR2]\]. In addition, co-morbidities that occur with aging (e.g., hypertension, diabetes, coronary artery disease) further increase the risk of CDIC and CRIC among cancer survivors \[[@CR3]--[@CR5]\]. Cardiovascular disease is the leading cause of non-cancer-related mortality in breast cancer survivors, making up 35% of deaths in those aged 50 years and above \[[@CR6]\]. The risk of cardiovascular-related death is higher in breast cancer survivors compared to women without breast cancer, and this increased risk typically occurs 7 years after the diagnosis of cancer \[[@CR7]\].

Current landscape {#Sec2}
=================

Anthracycline cardiomyopathy is the CDIC which has been most extensively studied. Historically, anthracycline cardiomyopathy was regarded as late in onset, progressive, and irreversible in nature \[[@CR8]\]. Unfortunately, unlike ischemic or idiopathic dilated cardiomyopathy, heart failure therapies were less effective in improving the prognosis of patients with advanced anthracycline cardiomyopathy presenting late after cancer treatment \[[@CR9]\]. Modern and contemporary approaches now allow detection of milder forms at an earlier stage when recovery is possible, and permanent dysfunction can be avoided. As prevention rather than rescue therapy is now the preferred strategy, physicians need tools to accurately predict patients with the highest risk of cardiotoxicity before the start of cancer treatment and also identify patients who develop subclinical cardiotoxicity early during the course of treatment. This allows for adjustment of chemotherapy regimens and/or initiation of cardioprotective strategies to reduce treatment-related mortality and morbidity without jeopardizing cancer prognosis.

There are presently varying definitions for CDIC. Typical histopathology features of anthracycline cardiomyopathy include loss of myofibrils and vacuolization of the cytoplasm \[[@CR10]\], but endomyocardial biopsy is seldom utilized now due to its invasive nature. The Cardiac Review and Evaluation Committee supervising trastuzumab clinical trials defines left ventricular (LV) dysfunction according to clinical presentation and reduction in left ventricular ejection fraction (LVEF) \[[@CR11]\]. On the other hand, in addition to clinical signs and symptoms, the latest Common Terminology Criteria for Adverse Events version 4 takes into account biomarker and cardiac imaging abnormalities when grading the severity of heart failure \[[@CR12]\].

The American Society of Echocardiography and European Association of Cardiovascular Imaging define cancer therapeutics-related cardiac dysfunction as a \> 10% drop in LVEF to below 53% \[[@CR13]\]. However practically, an LVEF of 50--54% may be considered 'low normal' in many cardiology departments, and more sensitive parameters, e.g., global longitudinal strain, can clarify if function is normal or reduced in patients where their LVEF has fallen into the 'low normal' range. Below 50% is accepted as abnormal. Unfortunately, LVEF as a diagnostic tool for early cardiomyopathy has poor sensitivity and variable reproducibility. LVEF may still remain normal despite the presence of myocardial injury \[[@CR14]\] because the heart undergoes ventricular remodeling in response to a cardiac insult in order to maintain adequate cardiac output \[[@CR15]\]. A fall in LVEF is only appreciable on imaging modalities after substantial cardiac injury or dysfunction is established and compensatory mechanisms are exhausted. However, advanced cardiac dysfunction, particularly when presenting with clinically decompensated heart failure, becomes more refractory to cardiac treatment.

Biomarkers offer a promising alternative solution for the early detection of cardiotoxicity as they overcome the shortcomings associated with imaging. As with echocardiography and magnetic resonance imaging, there is no radiation exposure with biomarkers. However, biomarkers are easier to perform and less time consuming for patients as it only involves a blood draw that can ideally be timed with other blood tests requested by the physicians. Biomarkers are also more reproducible than imaging since it avoids the issues of load dependency, technical factors, and inter- and intra-operator variability during result interpretation. Therefore, there is growing interest in biomarkers as a tool for cardiotoxicity risk prediction before cancer therapy, early detection of subclinical events during treatment, and identification of late complications during cancer survivorship.

Which cardiac biomarkers are currently helpful? {#Sec3}
===============================================

Biomarkers are measurable biologic variables that provide objective information about normal and pathogenic biological processes \[[@CR16]\], and they now routinely refer to circulating serum and plasma biochemicals present within the body. The perfect biomarker should improve clinical outcomes through better risk stratification, diagnostic certainty, and monitoring of disease progression and treatment response beyond pre-existing tests \[[@CR17]\]. The biomarker assay should also generate precise and reproducible results with a rapid turnaround time at an affordable cost \[[@CR17]\].

Troponin and brain natriuretic peptides are the two most established cardiac biomarkers for acute coronary syndrome and heart failure, respectively. Currently, there are no fixed recommendations regarding biomarkers in the detection of CDIC and CRIC. Results from trials performed to date are inconsistent and lack comparability mainly due to the lack of standardization in trial methodology. There is wide heterogeneity in terms of malignancy types, cancer treatment schedules, and definition of cardiotoxicity across the trials. Each trial also adopts different biomarker assays with variable threshold values, and the biomarkers are also sampled at different frequencies and time points with respect to the treatment regimen. In this paper, we will review the evidence surrounding troponin and brain natriuretic peptides in the context of CDIC and CRIC and discuss the role of upcoming biomarkers (Table [1](#Tab1){ref-type="table"}).Table 1Circulating biomarkers for cancer treatment-related cardiotoxicityTroponin Conventional troponin I and T High-sensitive troponin I and TNatriuretic peptides BNP NT-proBNPBiomarkers under investigation Myeloperoxidase MicroRNA Peripheral blood mononuclear cell gene expression profile ST-2 Galactin-3 High-sensitive CRP GDF-15*BNP* brain natriuretic peptide, *CRP* C-reactive protein, *GDF-15* growth differentiation factor 15, *NT-proBNP* N-terminal pro-brain natriuretic peptide

Troponin {#Sec4}
========

Cardiac troponin, specifically troponin I (TnI) and troponin T (TnT), is found within cardiac myocytes and is released into the serum when there is a disruption in sacrolemmal integrity. Previously, only conventional troponin assays were available to detect cardiac troponin at serum concentrations of 100 ng/L or above. However, technological advancements have led to the development of newer generation assays known as high-sensitive troponin assays, which can detect troponin at much lower concentrations. In clinical practice, troponin is a sensitive and specific marker of myocardial injury and is routinely measured in acute myocardial infarction for diagnostic and prognostic purposes \[[@CR18]\]. However, troponin can be elevated in other scenarios such as hypertensive emergencies, renal failure, rhabdomyolysis, sepsis, chronic poor vascular health, and drug-induced cardiotoxicity \[[@CR19]\], hence accounting for the low specificity of high-sensitive troponin assays \[[@CR20]\].

The utility of troponin in CDIC has been demonstrated in animal models. Herman et al. showed a positive correlation between rising TnI levels and cumulative doxorubicin doses in spontaneously hypertensive rats \[[@CR21]\]. A significant increase in TnT level, in association with reduced left ventricular contractility, was observed in daunorubicin-treated rabbits as compared to controls \[[@CR22]\]. Unfortunately, presence of troponin elevation implies that myocardial cell death has already occurred, hence raising questions about its role as an effective early marker of cardiotoxicity.

Role of conventional troponin in anthracycline-induced cardiotoxicity {#Sec5}
---------------------------------------------------------------------

### Troponin elevation during anthracycline treatment {#Sec6}

Majority of biomarker studies are conducted in the setting of anthracycline exposure among cancer patients, and they generally show that early troponin elevation precedes changes in LVEF. One study looked at serial changes in TnI and LVEF after every cycle of high-dose anthracycline-containing chemotherapy in 204 cancer patients \[[@CR23]\]. TnI was increased (\> 0.4 ng/ml) in 32% of the patients. After 7 months following the completion of treatment, patients with elevated TnI had significantly greater LVEF reduction compared with those without TnI elevation. In another 703 patients with predominantly breast cancer and lymphoma, persistent TnI elevation (\> 0.08 ng/ml) measured within 72 h of chemotherapy administration and at 1 month after the end of treatment portended the highest risk of cardiotoxicity (84%) over a mean follow-up duration of 20 months (*p* \< 0.001) compared with patients with transient or no TnI elevation \[[@CR24]\]. Cardiotoxicity in this study was defined as cardiac death, acute pulmonary edema, overt heart failure, asymptomatic LVEF reduction ≥ 25%, or life-threatening arrhythmias. TnT elevation was also observed in adult patients with hematological malignancies after a median of two anthracycline cycles, and a significantly greater reduction in LVEF on follow-up echocardiogram was seen in the patients with positive TnT compared to those without TnT rise (median LVEF reduction 10 versus 2%, *p* = 0.017) \[[@CR25]\]. In addition, greater extent of troponin elevation reflects worse LV dysfunction \[[@CR23], [@CR26]\].

### Biomarker-guided treatment strategies {#Sec7}

The notion of initiating all cancer patients on cardioprotective strategies prior to cancer treatment is gaining interest. Lipshultz et al. showed that administrating dexrazoxane to children suffering from acute leukemia prior to doxorubicin chemotherapy resulted in a significantly lower incidence of elevated TnT compared to those who did not receive dexrazoxane \[[@CR27]\]. The OVERCOME trial showed that pre-treating patients on high-dose chemotherapy with enalapril and carvedilol prevented deterioration in LVEF and led to statistically fewer deaths and heart failure events (*p* = 0.036) when compared to the control group \[[@CR28]\]. However, there are concerns of subjecting low-risk patients to unnecessary adverse events such as hypotension and renal dysfunction, which are common with heart failure therapies. Further, hemodynamic compromise may also occur since cancer patients are prone to sepsis and dehydration.

The following study by Cardinale et al. illustrates how troponin can be used to select high-risk cancer patients and help tailor patient-specific treatments. One hundred and fourteen high-risk cancer patients identified based on having early TnI elevation soon after high-dose chemotherapy were randomized to receive either 1-year treatment of enalapril or no treatment (control group) \[[@CR29]\]. At the end of 1 year, the enalapril group had significantly less cardiotoxicity than the control group (0 versus 43%; *p* \< 0.001). LVEF and LV volumes remained preserved in the enalapril group while the control group had progressive LVEF reduction and increase in LV volumes compared to baseline. The enalapril group also had significantly less heart failure and arrhythmic events (*p* \< 0.001 and *p* = 0.01, respectively) than the control group. Conversely, negative troponin values are also of equal importance---its high negative predictive value implies that such patients are at very low risk of cardiotoxicity \[[@CR24]\], and therefore are unlikely to require vigilant surveillance, cardioprotective medications, or cessation of their potentially curable cancer drug.

Role of conventional troponin in cardiotoxicity associated with other cancer therapies {#Sec8}
--------------------------------------------------------------------------------------

Evidence for the utility of troponin in detecting early cardiotoxicity with newer targeted cancer therapies is less robust compared with anthracyclines. Apart from predicting an increased risk of cardiotoxicity in breast cancer patients receiving trastuzumab (hazard ratio \[HR\] 22.9; 95% confidence interval \[CI\], 11.6 to 45.5; *p* \< 0.001), TnI elevation was also associated with a reduced likelihood of LVEF recovery (HR 2.88; 95% CI, 1.78 to 4.63; *p* \< 0.001) \[[@CR30]\]. However, in this study, 19% of TnI elevations occurred before trastuzumab treatment, suggesting that subclinical cardiac dysfunction due to other reasons (e.g., previous anthracycline, non-cardiac illness) was already present at baseline. Among 90 patients receiving molecular targeted therapies for metastatic solid tumors in a phase I trial, TnI elevation occurred in 11%, but this was not associated with clinically apparent cardiac events \[[@CR31]\]. In another observational single-center study, 9 out of 86 metastatic renal cell carcinoma patients on sorafenib or sunitinib experienced a rise in TnT \[[@CR32]\]. However, the magnitude of troponin increase was minimal, the sample population was small, and it was not clear if this correlated with LVEF reduction.

There is some data regarding the role of troponin in the detection of CRIC. Two studies looking at the effects of radiotherapy in breast cancer patients found that increased troponin levels occurred with higher cardiac radiation doses and it was also associated with deterioration in echocardiographic strain and diastology parameters \[[@CR33], [@CR34]\]. Unfortunately, the study populations were small, and the follow-up duration was too short to assess long-term clinical outcomes.

Role of conventional troponin in cancer survivorship {#Sec9}
----------------------------------------------------

Expert groups acknowledge the need for surveillance for asymptomatic late cardiotoxicity in cancer survivors \[[@CR35]--[@CR37]\], especially in the pediatric cohort where close to 60% have been exposed to anthracycline and/or cardiac irradiation \[[@CR38]\]. The experts agree that cardiac biomarkers should be performed. However, there are no formal guidelines advising on which biomarker to monitor and the surveillance frequency as supporting evidence is modest. Several studies have demonstrated the lack of correlation between troponin and LV dysfunction in childhood cancer survivors \[[@CR39]--[@CR41]\].

High-sensitive troponin {#Sec10}
=======================

There are several reasons why some trials fail to demonstrate an association between conventional troponin and LV dysfunction \[[@CR42]--[@CR45]\]. As previously mentioned, one explanation is the use of different biomarker assays, specifically the lower sensitivity conventional troponin assays. Troponin elevation in CDIC is often mild \[[@CR46]\] and may not be detectable on conventional assays. However, the newer high-sensitive troponin assays can detect troponin at very low concentrations \[[@CR20]\]. With increased sensitivity comes reduced specificity, and unfortunately not every raised reading using high-sensitive troponin assays in cancer patients reflects CDIC. Concomitant medical conditions such as acute kidney injury, sepsis, pulmonary embolism, and tachyarrhythmias are common in cancer patients and can increase troponin levels. In addition, there is the issue of biological variance in healthy individuals \[[@CR47]\]. Hence, physicians need to interpret positive troponin results with care and in the appropriate clinical context.

The use of high-sensitive troponin assays has since been integrated into several studies. Sawaya and his colleagues found that elevated high-sensitive troponin levels, together with echocardiographic markers of myocardial deformation, predicted the occurrence of cardiotoxicity among breast cancer patients receiving anthracycline and trastuzumab \[[@CR48], [@CR49]\], while Ky et al. demonstrated that an early rise in high-sensitivity TnI from baseline to 3 months was associated with an increased cardiotoxicity risk among similar patients \[[@CR50]•\]. In a subgroup analysis of the herceptin adjuvant (HERA) study, the presence of raised high-sensitive troponin before trastuzumab therapy was associated with a 2.4- to 4.5-fold increased risk of subsequent LVEF deterioration \[[@CR51]\].

Natriuretic peptides {#Sec11}
====================

Brain natriuretic peptide (BNP), together with its inactive N-terminal amino acid fragment NT-proBNP, is released by the ventricles in response to volume overload and/or wall stress \[[@CR52]\]. BNP induces natriuresis and diuresis in order to maintain euvolemia. Current guidelines recommend measuring natriuretic peptide levels in patients with heart failure as it provides valuable diagnostic, therapeutic, and prognostic information \[[@CR53], [@CR54]\].

Role of natriuretic peptides in anthracycline-induced cardiotoxicity {#Sec12}
--------------------------------------------------------------------

Natriuretic peptides are the next most commonly researched biomarker in the context of CRIC apart from troponin. They have been shown to be more sensitive markers of cardiotoxicity than echocardiography in several studies. In a prospective study by De Iuliis et al., NT-proBNP was significantly elevated at multiple time points after the completion of chemotherapy whereas there was no significant change in LVEF \[[@CR55]\]. The authors also showed that NT-proBNP was predictive of mortality at 1 year \[[@CR55]\]. Another study showed that persistent elevation of NT-proBNP taken early after high-dose chemotherapy was significantly associated with the development of LV systolic and diastolic dysfunction at 1-year follow-up \[[@CR56]\]. Among 205 children receiving doxorubicin for acute leukemia, elevation of NT-proBNP within the first 90 days of chemotherapy was predictive of cardiac dysfunction on echocardiography 4 years later \[[@CR57]\]. A recent study investigated whether serial BNP measurements taken before and after every cycle of anthracycline throughout the entire course of therapy predicted cardiotoxicity in 109 patients with primarily sarcoma and lymphoma \[[@CR58]\]. Results showed that in comparison to patients without cardiac events, BNP levels were significantly higher before and after every cycle of anthracycline in patients who experienced cardiac events (defined as asymptomatic LV dysfunction, symptomatic heart failure, symptomatic arrhythmia, acute coronary syndrome, or sudden cardiac death). There was also a tendency for patients with cardiac events to have a lower LVEF at the end of follow-up (*p* = 0.05) \[[@CR58]\].

Role of natriuretic peptides in cardiotoxicity associated with other cancer therapies {#Sec13}
-------------------------------------------------------------------------------------

In a single-center study consisting of 159 metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors and other targeted therapies, 43 patients (27%) developed asymptomatic cardiotoxicity defined by elevated NT-proBNP level and/or LVEF impairment \[[@CR59]\]. Twelve out of the 38 patients who had increased NT-proBNP levels also developed reduction in LVEF \[[@CR59]\]. In another group of patients receiving sunitinib for metastatic renal cell carcinoma, the risk of LV dysfunction was highest within the first treatment cycle \[[@CR60]\]. Although there was a statistically significant LVEF drop of 1.9% from baseline after the first treatment cycle (95% CI, − 3.2 to − 0.5, *p* = 0.007), this reduction was clinically not meaningful and was only transient after appropriate cardiac therapies. The mean BNP level did not show any significant change from baseline during the course of sunitinib treatment \[[@CR60]\].

Raised natriuretic peptide levels have also been reported in patients treated with thoracic irradiation and may reflect early cardiotoxicity before LVEF \[[@CR61]\]. Patients who received radiotherapy for left-sided breast cancer had significantly higher NT-proBNP levels at 6 months post-irradiation than those without radiotherapy \[[@CR62]\]. Increased doses of cardiac irradiation were also associated with a greater magnitude of natriuretic peptide elevation \[[@CR62], [@CR63]\].

Role of natriuretic peptides in cancer survivorship {#Sec14}
---------------------------------------------------

As discussed earlier, the utility of troponin in long-term surveillance of cancer survivors seems weak. However, brain natriuretic peptides appear to be potential early indicators of late cardiotoxicity during cancer survivorship as they have been associated with increased LV dimensions and echocardiographic features of systolic and diastolic dysfunction \[[@CR39]--[@CR41], [@CR56], [@CR57], [@CR64], [@CR65]\].

Limitations of natriuretic peptides {#Sec15}
-----------------------------------

There are investigators who fail to find an association between natriuretic peptides and cardiotoxicity \[[@CR48], [@CR49], [@CR50]•, [@CR66]\]. Reasons for conflicting natriuretic peptide trial results are similar to the troponin trials: retrospective design, small sample size, and lack of standardized biomarker reference ranges. Elderly individuals and females also have higher normal natriuretic peptide levels \[[@CR67], [@CR68]\], and worsening renal function increases natriuretic peptide levels \[[@CR69]\]. Recent evidence also suggests that cancer itself may potentially increase BNP levels through cancer-associated inflammation, with patients suffering from metastatic disease having significantly higher BNP levels than those without metastatic involvement \[[@CR70]\]. These confounding factors should definitely be taken into consideration during the interpretation of results.

New biomarkers in the pipeline {#Sec16}
==============================

There are several attractive biomarkers that show promise as future predictors of CDIC.

Myeloperoxidase {#Sec17}
---------------

Myeloperoxidase (MPO) is regarded as a marker of oxidative stress. It is released by neutrophils during periods of inflammation and oxidative stress \[[@CR50]•\], and the generation of excess free oxygen radicals is hypothesized to be pivotal in the pathogenesis of anthracycline cardiotoxicity \[[@CR71]\]. Among 78 breast cancer patients receiving doxorubicin and trastuzumab, an early rise in MPO levels from baseline to 3 months was associated with a higher risk of a first cardiotoxic event during the 15-month period of treatment \[[@CR50]•\]. In a later study involving the same patient cohort, the same authors showed that increases in MPO beyond 3 months of chemotherapy still remained predictive of increased cardiotoxicity risk over the course of treatment (HR 1.38; 95% CI, 1.10 to 1.71, *p* = 0.02) \[[@CR72]\].

MicroRNAs {#Sec18}
---------

MicroRNAs are small, non-coding RNA molecules that play an important role in the regulation of gene expression. They are involved in numerous cellular processes including those of the cardiovascular system \[[@CR73]\]. Within the heart itself, there is differential expression of microRNAs \[[@CR74]\], and some microRNAs have been linked to certain cardiovascular diseases. At present, miR-1, miR-133, miR-208, and miR-499 are cardiac miRNAs that are most extensively investigated \[[@CR75]\]. MiR-208 and miR-499, which are specifically found in cardiac myocytes, are significantly elevated in animal and human myocardial infarction models \[[@CR76]\] while miR-1 has been shown to provide therapeutic information in the setting of heart failure \[[@CR77]\].

Several studies have demonstrated encouraging results for the utility of microRNAs as biomarkers for CRIC. Doxorubicin caused upregulation of miR-146a in neonatal cardiac rat models \[[@CR78]\]. A recent study involving 33 children showed elevation of plasma miR-29b and miR-499 levels after anthracycline exposure, and the degree of elevation positively correlated with anthracycline dose and troponin rise \[[@CR79]\]. In another cohort of breast cancer patients receiving doxorubicin, an increase in miR-1 was significantly associated with LVEF reduction (*p* \< 0.001) and miR-1 was superior to TnI in predicting cardiotoxicity risk in the study \[[@CR80]\]. On the other hand, results of a study looking at the role of miR-208a in the setting of doxorubicin cardiotoxicity were disappointing \[[@CR81]\]. Despite this, investigators should continue to evaluate the role of microRNAs as they surpass existing biomarkers in several important aspects: (i) MicroRNAs are present in multiple body fluids \[[@CR82]\], (ii) they remain stable under extreme temperatures and pH, (iii) they have long half-life, (iv) they can be measured quantitatively using different methods \[[@CR83]\].

Peripheral blood mononuclear cell gene expression profile {#Sec19}
---------------------------------------------------------

Oxidative stress affects the immune response system. Patients exposed to continuous doxorubicin infusions have increased DNA-base oxidation within their peripheral blood mononuclear cells (PMBC) compared to pre-treatment \[[@CR84]\]. These changes within the PMBC result in detectable alterations in their gene expression profile \[[@CR85]\]. Todorova et al. found a high similarity between the gene expression profiles of PMBC and cardiac tissue in rats with doxorubicin cardiotoxicity, and the common genes identified were involved in oxidative stress response pathways \[[@CR86]\]. A subsequent study by the same group demonstrated a unique gene expression profile that was observed in breast cancer patients who developed doxorubicin cardiotoxicity but absent in those with preserved LVEF \[[@CR87]\].

Other novel biomarkers {#Sec20}
----------------------

There are other emerging biomarkers such as ST2, galactin-3, high-sensitivity C-reactive protein (hs-CRP), and growth differentiation factor 15 (GDF-15) but results are less encouraging. Several studies involving ST2 and galactin-3, which are markers of fibrosis, showed no significant association with cardiotoxicity \[[@CR45], [@CR49], [@CR50]•\]. Raised hs-CRP levels ≥ 3 mg/L were found to be predictive of reduced LVEF in breast cancer patients treated with trastuzumab in one study \[[@CR44]\], but there was no correlation between hs-CRP and cardiotoxicity risk in another study \[[@CR50]•\]. However, GDF-15, which is an indicator of inflammation and oxidative stress, shows promise in the detection of late anthracycline cardiotoxicity in pediatric cancer survivors \[[@CR43]\].

Future directions and conclusion {#Sec21}
================================

Circulating biomarkers are attractive tools in the detection of CDIC but no single measure is perfect. There are discordant data surrounding the utility of biomarkers in the pre-, during-, and post-cancer treatment periods. A multimodality strategy that incorporates several biomarkers with cardiac imaging appears to provide incremental value in highlighting patients at high risk of cardiotoxicity \[[@CR49], [@CR50]•\]. Genomics is a blossoming field, and the identification of genetic variants that predispose or protect one from adverse cardiotoxic side effects is a step towards precision medicine. An ongoing study by Skitch et al. aims to develop a risk prediction model for pediatric cancer patients through the integration of clinical risk factors, imaging parameters, biomarkers, and genomic factors \[[@CR88]\].

Before formal practice guidelines regarding the role of biomarkers can be implemented, there are many unanswered questions that need to be tackled. There is a need for new biomarkers that can detect myocardial injury earlier than troponin. Factors such as feasibility of repeated blood sampling and issue of cost-effectiveness must be considered. It is also crucial to establish evidence-based clinical strategies to prevent or treat cardiotoxicity while patients continue to receive effective life-saving cancer therapies. The Cardiac CARE trial (ISRCTN24439460) is an example of an ongoing biomarker-guided cardioprotection study that randomizes breast cancer patients with elevated troponin levels to receive either heart failure therapy or standard care prior to the initiation of chemotherapy \[[@CR89]\]. In summary, well-designed prospective trials with good statistical power and long-term follow-up are imperative to address these outstanding issues and hopefully they will provide physicians with the answers needed to manage this group of challenging patients.
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